Tarsier Pharma Ltd. is a late clinical stage biopharmaceutical company focused on developing and commercializing novel therapies for blinding inflammatory eye diseases. Their lead product candidate, TRS01, is a steroid-free eye drop designed to treat active non-infectious anterior uveitis (NIAU), and it aims to address the unmet medical need for safer alternatives to current steroid treatments. Tarsier is also developing TRS02, a slow-release intravitreal injection for other back-of-the-eye conditions. The company estimates the U.S. market for treating NIAU in patients with uveitic glaucoma to be over $5 billion annually.
Not disclosed in the provided filing text.
The proceeds from this offering will be used to fund clinical development activities, manufacturing processes, and to establish necessary infrastructures for marketing and commercialization of their product candidates.
This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.
It is classified under Pharmaceutical Preparations.
Tarsier Pharma Ltd. has filed 2 times, starting with a F1/A on Jul 15, 2026.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Tarsier Pharma Ltd..
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/tarsier-pharma" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Tarsier Pharma Ltd. — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/tarsier-pharma?theme=light as the src instead.
https://www.discoveripo.com/ipo/tarsier-pharma/opengraph-image
Tarsier Pharma Ltd. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/tarsier-pharma?utm_source=embed&utm_medium=text&utm_campaign=tarsier-pharma
Get emailed when Tarsier Pharma Ltd.'s terms, price, or expected date change — no weekly noise, just this company.
Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Aug 27, 2026.
View the original filing on SEC EDGAR →How this offering's SEC filings changed over time. Only SEC-sourced filings are compared here — exchange calendars publish only their latest figures, with no history to diff against.
Initial filing.
No tracked deal terms changed in this amendment.
Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy